
DD Stock Forecast & Price Target
DD Analyst Ratings
Bulls say
DuPont de Nemours is supported by strong healthcare and water franchises, where demand in personal protection, medical packaging, industrial water, and semiconductor/ultrapure water is driving mid- to high-single-digit organic growth. Its Q3 beat showed broad-based operational momentum, with sales of $1.87B, EBITDA of $469MM, 30.4% segment margins in Healthcare & Water Technologies, and expanding margins in Diversified Industrials from aerospace, EV batteries, and productivity actions. The company’s outlook is further reinforced by low leverage at 1.1x, robust free cash flow, substantial buybacks, and optionality for accretive M&A as it continues transforming into a multi-industrial peer.
Bears say
DuPont de Nemours is viewed negatively because its downside case still depends on a 2026E EPS of only $7.43 to $7.20, implying that earnings power remains vulnerable if conditions worsen. The core concerns are delayed synergy realization, integration friction, and an imperfect spin strategy, all of which could prevent management from unlocking the benefits expected from the 2019 restructuring. On top of that, continued weakness in electronics and construction, plus a slower China and North America recovery, could pressure the healthcare- and water-led profit base despite the company’s diversified specialty chemicals portfolio.
This aggregate rating is based on analysts' research of DuPont de Nemours and is not a guaranteed prediction by Public.com or investment advice.
DD Analyst Forecast & Price Prediction
Start investing in DD
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DuPont de Nemours (DD) Forecast
DD Analyst Forecast & Price Prediction
Start investing in DD
Order type
Buy in
Order amount
Est. shares
0 shares